Buy Granules India; target of Rs 950: Emkay Global Financial

What happened

Emkay Global Financial maintained a Buy rating on Granules India with a target of Rs 950. The company's 2QFY27 EBITDA (earnings before interest, tax, depreciation and amortisation) met estimates, as sales beat forecasts but margin weakness offset that gain.

Confirmed

Global impact / market context

Lower gross margin, which means profit left after direct production costs, plus higher input costs and a delayed return to normal operating expenses, explain why Emkay cut earnings estimates by about 4%. Investors holding the stock face a trade-off between steady sales growth and near-term profit pressure.

Analyst inference

The USFDA inspection outcome at the Gagillapur plant is a binary event, meaning a clear pass or fail. If the warning letter status stays unchanged, earnings should be broadly neutral. A positive outcome could lift the shares toward the Rs 950 target.

Analyst inference

What to watch

1. Management said observations from the recent Gagillapur reinspection were not linked to those in the warning letter, and Gagillapur capacity utilization remains unaffected while Genome Valley utilization should rise toward optimal levels within two quarters. Confirmed
2. Track whether gross margin recovers as input costs ease and product mix improves, and whether operating expense normalization arrives within a quarter, since Emkay cut earnings estimates by about 4% on moderated margins. Proposed
3. Watch the USFDA inspection result for Gagillapur: an adverse outcome could push complete resolution to CY28, while a clean result may reduce uncertainty and support re-rating toward the Rs 950 target. Analyst inference

Evidence

• Original source link unavailable